中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2014年
12期
31-33
,共3页
尤瑞克林%奥扎格雷钠%急性脑梗死
尤瑞剋林%奧扎格雷鈉%急性腦梗死
우서극림%오찰격뢰납%급성뇌경사
Urinary kallidinogenase%sodium ozagrel%acute cerebral infarction
目的：观察尤瑞克林联合奥扎格雷钠治疗急性脑梗死的临床效果。方法选取我院神经内科2012-01-2013-12收治的急性脑梗死患者163例，按随机数字表法分为对照组与观察组，对照组采取奥扎格雷钠80 mg加入100 mL 0.9％氯化钠注射液中静滴，2次／d ，观察组在对照组治疗的基础上加用尤瑞克林0.15 PNAU 加入100 mL 0.9％氯化钠注射液中静滴，1次／d ，2组均治疗14 d为1个疗程。治疗1个疗程后按美国国立卫生研究院卒中量表评分（NIHSS ）评定2组患者神经功能恢复程度及临床疗效，记录2组治疗过程中的不良反应并对比分析。结果2组治疗后 NIHSS评分均较治疗前有所降低，观察组NIHSS评分显著低于对照组，差异有统计学意义（P＜0.05）；对照组总有效率79.0％，观察组为93.9％，2组比较差异有统计学意义（P＜0.01）；2组不良反应均较轻微，差异无统计学意义（P＞0.05）。结论尤瑞克林联合奥扎格雷钠治疗急性脑梗死具有较好疗效，安全可靠，值得临床推广。
目的：觀察尤瑞剋林聯閤奧扎格雷鈉治療急性腦梗死的臨床效果。方法選取我院神經內科2012-01-2013-12收治的急性腦梗死患者163例，按隨機數字錶法分為對照組與觀察組，對照組採取奧扎格雷鈉80 mg加入100 mL 0.9％氯化鈉註射液中靜滴，2次／d ，觀察組在對照組治療的基礎上加用尤瑞剋林0.15 PNAU 加入100 mL 0.9％氯化鈉註射液中靜滴，1次／d ，2組均治療14 d為1箇療程。治療1箇療程後按美國國立衛生研究院卒中量錶評分（NIHSS ）評定2組患者神經功能恢複程度及臨床療效，記錄2組治療過程中的不良反應併對比分析。結果2組治療後 NIHSS評分均較治療前有所降低，觀察組NIHSS評分顯著低于對照組，差異有統計學意義（P＜0.05）；對照組總有效率79.0％，觀察組為93.9％，2組比較差異有統計學意義（P＜0.01）；2組不良反應均較輕微，差異無統計學意義（P＞0.05）。結論尤瑞剋林聯閤奧扎格雷鈉治療急性腦梗死具有較好療效，安全可靠，值得臨床推廣。
목적：관찰우서극림연합오찰격뢰납치료급성뇌경사적림상효과。방법선취아원신경내과2012-01-2013-12수치적급성뇌경사환자163례，안수궤수자표법분위대조조여관찰조，대조조채취오찰격뢰납80 mg가입100 mL 0.9％록화납주사액중정적，2차／d ，관찰조재대조조치료적기출상가용우서극림0.15 PNAU 가입100 mL 0.9％록화납주사액중정적，1차／d ，2조균치료14 d위1개료정。치료1개료정후안미국국립위생연구원졸중량표평분（NIHSS ）평정2조환자신경공능회복정도급림상료효，기록2조치료과정중적불량반응병대비분석。결과2조치료후 NIHSS평분균교치료전유소강저，관찰조NIHSS평분현저저우대조조，차이유통계학의의（P＜0.05）；대조조총유효솔79.0％，관찰조위93.9％，2조비교차이유통계학의의（P＜0.01）；2조불량반응균교경미，차이무통계학의의（P＞0.05）。결론우서극림연합오찰격뢰납치료급성뇌경사구유교호료효，안전가고，치득림상추엄。
Objective To observe the clinical effect of urinary kallidinogenase combined with sodium ozagrel in the treat-ment of acute cerebral infarction. Methods 163 patients with acute cerebral infarction were selected in the department of Neu-rology in our hospital from January 2012 to December 2013 ,and randomly divided into control group and observation group ,81 cases in the control group were treated by sodium ozagrel 80mg added 100 mL 0.9% Sodium Chloride Injection intravenous drip ,2 times /d ,82 cases of the observation group were treated by urinary kallidinogenase 0.15 PNAU added 100mL 0.9% so-dium chloride Injection intravenous drip based on the control group treatment ,1 times /d. Both groups were treated for 14 days as one course. After 1 course of treatment ,USA National Institutes of Health Stroke Scale (NIHSS) was used to evaluate the degree of nerve function recovery and clinical efficacy of patients of the two groups ,adverse reactions of the two groups in the course of treatment were recorded and compared. Results After treatment ,NIHSS scores of the two groups were lower than those before treatment ;NIHSS score of patients in the observation group were significantly lower than that of the control group ,the difference was statistically significant (P<0.05);the control group's total effectiveness was 79% ,and that of the observation group was 93.9% ,there was significant difference between the two groups (P<0.01);the adverse reactions in two groups were light ,no significant difference (P>0.05).Conclusion The clinical effectiveness of urinary kallidinogenase com-bined with sodium ozagrel in the treatment of acute cerebral infarction is good ,safe and reliable ,and worthy of clinical applica-tion.
